Evidence map›Paper›PMID 33193348›Full record

ArticleFrontiers in immunology2020

Opportunities for Antigen Discovery in Metastatic Breast Cancer.

Ashwani K Sood, Michael Nemeth, Jianmin Wang, Yun Wu, Shipra Gandhi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ashwani K SoodDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Michael NemethDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Jianmin WangDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Yun WuDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, United States.
Shipra GandhiDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Institutional Career DevelopmentKL2TR001413 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 2015 to 2024
$4.2M
NCATS NIH HHS KL2 TR001413NCATS NIH HHS UL1 TR001412
6 · The paper itself

Abstract

Immune checkpoint inhibitor-based immunotherapy (ICI) of breast cancer is currently efficacious in a fraction of triple negative breast cancers (TNBC) as these cancers generally carry high tumor mutation burden (TMB) and show increased tumor infiltration by CD8

Indexed as

Antigens, NeoplasmAntigens, ViralAutoantigensCD8-Positive T-LymphocytesEndogenous RetrovirusesFemaleHumansImmune ToleranceImmunity, CellularImmunotherapyT-Lymphocytes, RegulatoryTriple Negative Breast NeoplasmsAntigens, NeoplasmAntigens, ViralAutoantigensCDK4/6 inhibitiondecreased autoimmunityincreased tumor immunityin situ anti-tumor immunitysynergizing TAA and TNA

Identifiers

PMID33193348
PMCPMC7661635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.